The EC approved Libtayo – a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells – based on data from the global open-label, multi-centre phase 3 EMPOWER ...

Moreover, most previously-untreated NSCLC patients treated with Keytruda do so in combination with chemo, so the new data – if added to Libtayo's label – could allow the drug to directly ...

For example, should DUPIXENT slow to 15% growth, while LIBTAYO continues rapidly as the label is expanded to include CSCC an overall revenue growth for Regeneron of ~10% seems achievable.

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab ... based on data from the EMPOWER-Cervical 1 phase 3 trial. This open-label ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

open-label, dose-finding clinical trial, was designed to evaluate the agent's anti-tumor activity in combination with PD-(L)1 inhibition. The investigation will determine whether administering low ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... is based on data from the open-label, multi-centre, randomised Phase ...

Libtayo reached $367M in Q4 global sales ... including durability and potential label enhancements, strengthens its competitive position. Tyler Van Buren, TD Cowen: Asked about the timing of ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...